Vistusertib,AZD4547,Capivasertib,Sapitinib,Selumetinib,Vandetanib,durvalumab,savolitinib,Olaparib
astrazeneca,sanofi,hutchmed,merck,otsuka
['sclc', 'nsclc', 'lung']
#ctdna #tumorfraction highly prognostic in the context of #maintenance treatment for #nsclc. no benefit from #icbs if tumor fraction elevated. our presentation at #asco23 on safir 02 lung rct. 
M.d., medical oncologist 
Gustave Roussy
PhD at University of Bologna